Robert I. Haddad - Concepedia

Author

Robert I. Haddad

Also Known As

A HADDAD, A Haddad, A. Haddad, Andrea Haddad, Bauman, Jessica, Douglas B. Chepeha, Gregory Wolf, Haddad, A., Haddad, Robert, Ian Yang

822

Publications

73.7K

Citations

106

H-Index

167

Concepts

All Affiliations

Dana-Farber Cancer Institute Brigham and Women's Hospital Harvard University Dana-Farber Brigham Cancer Center The University of Texas MD Anderson Cancer Center

About

Robert I. Haddad is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	32	55	7.8K
2	Engineering	9	9	599
3	Arts	1	1	230
4	Education	1	1	24
5	Management	1	1	19

Robert I. Haddad

251

Publications

34.7K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, New England Journal of Medicine	2016	4.9K
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer Marshall R. Posner, Diáne Hershock, C. Blajman, New England Journal of Medicine	2007	1.7K
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology David G. Pfister, Sharon Spencer, David J. Adelstein, Journal of the National Comprehensive Cancer Network Cancer ManagementPathologyOncologyNasopharyngeal CancerNeck Oncology	2020	1.3K
Recent Advances in Head and Neck Cancer Robert I. Haddad, Dong M. Shin New England Journal of Medicine PathologyVoice SurgeryTreatment ResistanceTumor BiologyOral Cancer	2008	924
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta, Journal of Clinical Oncology Antitumor ActivityImmunologyPathologyPharmacotherapyImmunotherapy	2016	846
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression Robert L. Ferris, George R. Blumenschein, Jérôme Fayette, Oral Oncology Neoadjuvant TherapyCheckmate 141MedicineTumor Pd-l1 ExpressionPathology	2018	776
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial Robert I. Haddad, Anne O’Neill, Guilherme Rabinowits, The Lancet Oncology Advanced HeadConcurrent ChemoradiotherapyRadiation TherapyMedicineRandomised Phase 3	2013	735
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors Diana Miao, Claire A. Margolis, Natalie I. Vokes, Nature Genetics Cancer ImmunosurveillanceMedicineImmunologyCancer GenomicsGenomic Correlates	2018	683
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister, Journal of Clinical Oncology Neck CancerNeoadjuvant TherapyCancer ManagementImmunologyPathology	2017	641
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018 A. Dimitrios Colevas, Sue S. Yom, David G. Pfister, Journal of the National Comprehensive Cancer Network	2018	620

Page 1